0 Évaluations
ID

44205

Description

Study ID: 101468/205 Clinical Study ID: 101468/205 Study Title:A 12-Week, Double-Blind, Placebo Controlled, Parallel Group Study to Assess the Efficacy and Safety of Ropinirole XR (Extended Release) in Patients with Restless Legs Syndrome Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00197080 Sponsor: GlaxoSmithKline Phase: phase 3 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: Modutab,ZIPEREVE,ZEPREVE,REPREVE,ADARTREL,REQUIP,Zygara; Zygara,ZIPEREVE,ZEPREVE,Requip Depot,REQUIP,REPREVE,Modutab,ADARTREL Study Indication: Restless Legs Syndrome

Mots-clés

Versions (2)
  1. 12/02/2019 12/02/2019 -
  2. 20/09/2021 20/09/2021 -
Détendeur de droits

GlaxoSmithKline

Téléchargé le

20 septembre 2021

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY-NC 3.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

  • Plus récent
  • Plus ancien
  • Favori
  • Plus récent
    • Plus récent
    • Plus ancien
    • Favori

    Aucun commentaire

    Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

    Efficacy and Safety of Ropinirole XR (Extended Release) in Patients with Restless Legs Syndrome NCT00197080

    Anglais

    Baseline - Eligibility Question

    1 Formulaires  
    Eligibility Question
    Description

    Eligibility Question

    Alias
    UMLS CUI-1
    C1516637
    Did the subject meet all the entry criteria?
    Description

    If No, ✔ all boxes corresponding to violations of any inclusion/exclusion criteria. Do not enter the subject into the study if they failed any inclusion or exclusion criteria below.

    Type de données

    boolean

    Alias
    UMLS CUI [1]
    C1516637
    Inclusion Criteria
    Description

    Inclusion Criteria

    Alias
    UMLS CUI-1
    C1512693
    1. Subjects diagnosed with RLS using the RLS Diagnostic Clinical Interview and the International RLS Study Group (IRLSSG) Diagnostic Criteria at the Screening Visit.
    Description

    1. Subjects diagnosed with RLS using the RLS Diagnostic Clinical Interview and the International RLS Study Group (IRLSSG) Diagnostic Criteria at the Screening Visit.

    Type de données

    boolean

    Alias
    UMLS CUI [1]
    C0035258
    UMLS CUI [2,1]
    C1537061
    UMLS CUI [2,2]
    C0035258
    2. Subjects > 18 years and < 80 years of age.
    Description

    2. Subjects > 18 years and < 80 years of age

    Type de données

    boolean

    Alias
    UMLS CUI [1]
    C0001779
    3. Subjects have had RLS symptoms with a history of a minimum of 20 evening and nights of RLS episodes during the month prior to the Screening Visit (e.g., any combination of evenings and/or nights for >20 days). In the case of a subject currently receiving medication for the treatment of RLS at the Screening Visit, this inclusion criterion can be waived. However, the subject must discontinue and washout any previous medication for the treatment of RLS or sleep prior to the Baseline Visit (Day 0). The minimum discontinuation period for washout is generally 5 half-lives of the medication or 7 consecutive nights medication-free prior to baseline, whichever is the longer period.
    Description

    3. Restless Legs Syndrome; Frequencies (time pattern) | Restless Legs Syndrome; Pharmaceutical Preparations; Washout Period

    Type de données

    boolean

    Alias
    UMLS CUI [1,1]
    C0035258
    UMLS CUI [1,2]
    C0439603
    UMLS CUI [2,1]
    C0035258
    UMLS CUI [2,2]
    C0013227
    UMLS CUI [2,3]
    C1710661
    4.During the Washout and Screening Phase, RLS symptoms must be present for at least 4 of the last 7 evening and nights immediately prior to the Baseline Visit (e.g., any combination of evenings and/or nights for >4 days).
    Description

    4.During the Washout and Screening Phase, RLS symptoms must be present for at least 4 of the last 7 evening and nights immediately prior to the Baseline Visit (e.g., any combination of evenings and/or nights for >4 days).

    Type de données

    boolean

    Alias
    UMLS CUI [1,1]
    C1710661
    UMLS CUI [1,2]
    C0035258
    UMLS CUI [1,3]
    C0439603
    UMLS CUI [2,1]
    C0220908
    UMLS CUI [2,2]
    C0035258
    UMLS CUI [2,3]
    C0439603
    5.Subjects with a total score > 15 on the IRLS Rating Scale at baseline.
    Description

    5.Subjects with a total score > 15 on the IRLS Rating Scale at baseline.

    Type de données

    boolean

    Alias
    UMLS CUI [1,1]
    C0449820
    UMLS CUI [1,2]
    C0681889
    UMLS CUI [1,3]
    C0035258
    6.Subjects with RLS symptoms that cause significant sleep impairment based on clinical judgment and guided by subject response to question 4 of the IRLS Rating Scale (e.g., Ordinarily this will include a response of (3) severe or (4) very severe sleep disturbance) at the Baseline Visit.
    Description

    6.Subjects with RLS symptoms that cause significant sleep impairment based on clinical judgment and guided by subject response to question 4 of the IRLS Rating Scale (e.g., Ordinarily this will include a response of (3) severe or (4) very severe sleep disturbance) at the Baseline Visit.

    Type de données

    boolean

    Alias
    UMLS CUI [1,1]
    C0035258
    UMLS CUI [1,2]
    C0851578
    7.Subjects must be experiencing RLS symptoms requiring treatment prior to bedtime, but no earlier than 5:00 PM.
    Description

    7.Subjects must be experiencing RLS symptoms requiring treatment prior to bedtime, but no earlier than 5:00 PM.

    Type de données

    boolean

    Alias
    UMLS CUI [1,1]
    C0035258
    UMLS CUI [1,2]
    C1457887
    UMLS CUI [1,3]
    C0332121
    UMLS CUI [1,4]
    C0521112
    8. Subjects must have given written informed consent prior to any specific study procedures.
    Description

    8. Subjects must have given written informed consent prior to any specific study procedures.

    Type de données

    boolean

    Alias
    UMLS CUI [1]
    C0021430
    Exclusion criteria
    Description

    Exclusion criteria

    Alias
    UMLS CUI-1
    C0680251
    1. Subjects requiring treatment of daytime RLS symptoms (daytime defined as 7:00 AM until 5:00 PM).
    Description

    1. Subjects requiring treatment of daytime RLS symptoms (daytime defined as 7:00 AM until 5:00 PM).

    Type de données

    boolean

    Alias
    UMLS CUI [1,1]
    C0035258
    UMLS CUI [1,2]
    C0087111
    UMLS CUI [1,3]
    C1457887
    UMLS CUI [1,4]
    C0332169
    2. Signs of secondary RLS (e.g. end stage renal disease, iron deficient anemia or pregnancy at Baseline Visit).
    Description

    2. Signs of secondary RLS (e.g. end stage renal disease, iron deficient anemia or pregnancy at Baseline Visit).

    Type de données

    boolean

    Alias
    UMLS CUI [1]
    C1261469
    UMLS CUI [2]
    C0022661
    UMLS CUI [3]
    C0162316
    UMLS CUI [4]
    C0032961
    3. Subjects with a serum ferritin level of < 10 mcg/L (ng/mL) that has not resolved by the time of the Baseline Visit.
    Description

    3. Subjects with a serum ferritin level of < 10 mcg/L (ng/mL) that has not resolved by the time of the Baseline Visit.

    Type de données

    boolean

    Alias
    UMLS CUI [1]
    C0696113
    4. Subjects having a clinically significant abnormal lab, ECG, or physical exam findings not resolved by time of baseline examinations. Abnormal 12-lead ECG findings include, but are not limited to the following: myocardial ischemia, clinically significant conduction abnormalities, or clinically significant arrhythmias
    Description

    Laboratory test result abnormal; Clinical Significance | Electrocardiogram abnormal; Clinical Significance | Physical Examination; Abnormal; Clinical Significance | Myocardial Ischemia | Abnormal cardiac conduction; Clinical Significance | Cardiac Arrhythmia; Clinical Significance

    Type de données

    boolean

    Alias
    UMLS CUI [1,1]
    C0438215
    UMLS CUI [1,2]
    C2826293
    UMLS CUI [2,1]
    C0522055
    UMLS CUI [2,2]
    C2826293
    UMLS CUI [3,1]
    C0031809
    UMLS CUI [3,2]
    C0205161
    UMLS CUI [3,3]
    C2826293
    UMLS CUI [4]
    C0151744
    UMLS CUI [5,1]
    C0232219
    UMLS CUI [5,2]
    C2826293
    UMLS CUI [6,1]
    C0003811
    UMLS CUI [6,2]
    C2826293
    5. Subjects who suffer from a primary sleep disorder other than RLS that may significantly affect the symptoms of RLS (e.g. narcolepsy, sleep terror disorder, sleepwalking disorder, breathing related sleep disorder).
    Description

    5. Subjects who suffer from a primary sleep disorder other than RLS that may significantly affect the symptoms of RLS (e.g. narcolepsy, sleep terror disorder, sleepwalking disorder, breathing related sleep disorder).

    Type de données

    boolean

    Alias
    UMLS CUI [1,1]
    C0236991
    UMLS CUI [1,2]
    C0035258
    UMLS CUI [1,3]
    C0205394
    UMLS CUI [2,1]
    C0035258
    UMLS CUI [2,2]
    C1457887
    UMLS CUI [3]
    C0027404
    UMLS CUI [4,1]
    C0851578
    UMLS CUI [4,2]
    C0037320
    UMLS CUI [5]
    C0037672
    UMLS CUI [6]
    C0236845
    6. Subjects diagnosed with movement disorders (e.g. Parkinson’s Disease, dyskinesias, and dystonias).
    Description

    6. Subjects diagnosed with movement disorders (e.g. Parkinson’s Disease, dyskinesias, and dystonias).

    Type de données

    boolean

    Alias
    UMLS CUI [1]
    C0026650
    UMLS CUI [2]
    C0030567
    UMLS CUI [3]
    C0013384
    UMLS CUI [4]
    C0013421
    7. Subjects who have medical conditions which, in the opinion of the investigator, could affect efficacy assessments or clinically significant or unstable medical conditions that present a safety concern. These may include, but are not limited to the following disorders: diabetes, peripheral neuropathy, rheumatoid arthritis, fibromyalgia syndrome, symptomatic orthostatic hypotension, severe cardiovascular disease, hepatic or renal failure, pleuro-pulmonary fibrosis).
    Description

    7. Subjects who have medical conditions which, in the opinion of the investigator, could affect efficacy assessments or clinically significant or unstable medical conditions that present a safety concern.

    Type de données

    boolean

    Alias
    UMLS CUI [1,1]
    C0012634
    UMLS CUI [1,2]
    C1280519
    UMLS CUI [1,3]
    C0220825
    UMLS CUI [2,1]
    C0012634
    UMLS CUI [2,2]
    C0443343
    UMLS CUI [2,3]
    C0036043
    UMLS CUI [2,4]
    C2699424
    UMLS CUI [3]
    C0011849
    UMLS CUI [4]
    C0031117
    UMLS CUI [5]
    C0003873
    UMLS CUI [6]
    C0016053
    UMLS CUI [7]
    C0740482
    UMLS CUI [8,1]
    C0007222
    UMLS CUI [8,2]
    C0205082
    UMLS CUI [9]
    C0035078
    UMLS CUI [10]
    C0085605
    UMLS CUI [11]
    C0034069
    8.Subjects with augmentation and/or end-of-dose rebound symptoms at baseline. Augmentation is defined as RLS symptoms that occurred while on treatment and occur >2 hours earlier than they did before, symptoms which are more severe than when not treated, symptoms which start after less time at rest than they did before treatment, or symptoms which involve other parts of the body, such as the arms or trunk.
    Description

    8.Subjects with augmentation and/or end-of-dose rebound symptoms at baseline.

    Type de données

    boolean

    Alias
    UMLS CUI [1]
    C1293122
    UMLS CUI [2]
    C0549262
    UMLS CUI [3,1]
    C0035258
    UMLS CUI [3,2]
    C1457887
    UMLS CUI [3,3]
    C2745955
    UMLS CUI [4,1]
    C0035258
    UMLS CUI [4,2]
    C1457887
    UMLS CUI [4,3]
    C0205082
    UMLS CUI [5,1]
    C0035258
    UMLS CUI [5,2]
    C1457887
    UMLS CUI [5,3]
    C0229962
    9. Subjects with a history of alcohol or substance abuse within the past year.
    Description

    9. Subjects with a history of alcohol or substance abuse within the past year.

    Type de données

    boolean

    Alias
    UMLS CUI [1,1]
    C0085762
    UMLS CUI [1,2]
    C1299544
    10. Subjects with a diastolic blood pressure >110mmHg or <50mmHg or systolic blood pressure > 180mmHg or <90mmHg at the Screening or Baseline Visit.
    Description

    10. Subjects with a diastolic blood pressure >110mmHg or <50mmHg or systolic blood pressure > 180mmHg or <90mmHg at the Screening or Baseline Visit.

    Type de données

    boolean

    Alias
    UMLS CUI [1]
    C0428883
    UMLS CUI [2]
    C0871470
    11. Subjects taking any medication known to induce drowsiness, affect RLS or sleep and that have not been discontinued prior to the Baseline Visit. These medications include the following: - antidepressants (tricyclic antidepressants, noradrenaline [norepinephrine]/ serotonin re-uptake inhibitors, selective serotonin re-uptake inhibitors, bupropion), anticonvulsants, opioids (including propoxyphene and oxycodone), anxiolytics, all sedatives/hypnotics (including benzodiazepines), lithium, oral neuroleptics, stimulants (including methylphenidate), antipsychotics, dopamine agonists, dopamine antagonists, clonidine, and sedating antihistamines (e.g. chlorpheniramine, diphenhydramine, hydroxyzine) or any preparations containing these antihistamines - The minimum discontinuation period is generally 5 half lives or 7 consecutive evening/nights medication free, prior to baseline, whichever is the longer period. Exceptions to this general rule are as follows: fluoxetine, monoamine oxidase inhibitors: 4 weeks; depot neuroleptics: 12 weeks. - Exceptions may be made in the case of subjects who have been taking stable doses of one of the excluded medications for at least 3 months prior to study start and it can be confirmed that the medication is not affecting the subject’s symptoms of RLS or sleep. These exceptions will be made on a case by case basis after consultation with the sponsor. For these exceptions, the dose of the excluded medication must remain stable throughout the duration of the study.
    Description

    11. Subjects taking any medication known to induce drowsiness, affect RLS or sleep and that have not been discontinued prior to the Baseline Visit.

    Type de données

    boolean

    Alias
    UMLS CUI [1,1]
    C0013227
    UMLS CUI [1,2]
    C0013144
    UMLS CUI [1,3]
    C0035258
    UMLS CUI [1,4]
    C0392760
    UMLS CUI [1,5]
    C0013227
    UMLS CUI [1,6]
    C0013144
    UMLS CUI [1,7]
    C0035258
    UMLS CUI [1,8]
    C0037313
    UMLS CUI [1,9]
    C0457454
    UMLS CUI [2]
    C0003290
    UMLS CUI [3]
    C0162758
    UMLS CUI [4]
    C0003286
    UMLS CUI [5,1]
    C0242402
    UMLS CUI [5,2]
    C0033493
    UMLS CUI [5,3]
    C0030049
    UMLS CUI [6]
    C0040616
    UMLS CUI [7,1]
    C0020592
    UMLS CUI [7,2]
    C0005064
    UMLS CUI [8]
    C0023870
    UMLS CUI [9,1]
    C0040615
    UMLS CUI [9,2]
    C0442027
    UMLS CUI [10,1]
    C0304402
    UMLS CUI [10,2]
    C0025810
    UMLS CUI [11]
    C0040615
    UMLS CUI [12]
    C0178601
    UMLS CUI [13]
    C0242702
    UMLS CUI [14]
    C0009014
    UMLS CUI [15,1]
    C1955826
    UMLS CUI [15,2]
    C0008281
    UMLS CUI [15,3]
    C0012522
    UMLS CUI [15,4]
    C0020404
    UMLS CUI [16,1]
    C0457454
    UMLS CUI [16,2]
    C1524031
    UMLS CUI [17]
    C0016365
    UMLS CUI [18]
    C0026457
    UMLS CUI [19,1]
    C0040615
    UMLS CUI [19,2]
    C0086129
    12. Withdrawal, introduction, or change in dose of hormone replacement therapy (HRT) and/or any drug known to substantially inhibit CYP1A2 (e.g. ciprofloxacin, cimetidine, fluvoxamine, HRT) or induce CYP1A2 (e.g. tobacco, omeprazole) within 7 days prior to Baseline Visit. Subjects already on these agents may be enrolled, but must remain on stable doses of the agents from 7 days prior to Baseline Visit through to the follow-up visit at end of study.
    Description

    12. Withdrawal, introduction, or change in dose of hormone replacement therapy (HRT) and/or any drug known to substantially inhibit CYP1A2 (e.g. ciprofloxacin, cimetidine, fluvoxamine, HRT) or induce CYP1A2 (e.g. tobacco, omeprazole) within 7 days prior to Baseline Visit.

    Type de données

    boolean

    Alias
    UMLS CUI [1,1]
    C0282402
    UMLS CUI [1,2]
    C2349954
    UMLS CUI [2,1]
    C0282402
    UMLS CUI [2,2]
    C0579004
    UMLS CUI [3,1]
    C0282402
    UMLS CUI [3,2]
    C1707811
    UMLS CUI [4,1]
    C1827504
    UMLS CUI [4,2]
    C0008809
    UMLS CUI [4,3]
    C0008783
    UMLS CUI [4,4]
    C0085228
    UMLS CUI [4,5]
    C0282402
    UMLS CUI [5,1]
    C1827490
    UMLS CUI [5,2]
    C0543414
    UMLS CUI [5,3]
    C0028978
    13. Subjects who have exhibited intolerance to ropinirole or any other dopamine agonist.
    Description

    13. Subjects who have exhibited intolerance to ropinirole or any other dopamine agonist.

    Type de données

    boolean

    Alias
    UMLS CUI [1,1]
    C1744706
    UMLS CUI [1,2]
    C0244821
    UMLS CUI [2,1]
    C1744706
    UMLS CUI [2,2]
    C0178601
    14. Night workers or any others whose sleeping habits are incompatible with the study design, or who would be required to make significant changes to their bedtime during the course of the study.
    Description

    14. Night workers or any others whose sleeping habits are incompatible with the study design, or who would be required to make significant changes to their bedtime during the course of the study.

    Type de données

    boolean

    Alias
    UMLS CUI [1]
    C0555008
    UMLS CUI [2,1]
    C0547101
    UMLS CUI [2,2]
    C4698019
    UMLS CUI [2,3]
    C0035171
    UMLS CUI [3,1]
    C0547101
    UMLS CUI [3,2]
    C4698019
    UMLS CUI [3,3]
    C0680104
    15. Participation in any clinical drug or device trial in the one month prior to the Baseline Visit.
    Description

    15. Participation in any clinical drug or device trial in the one month prior to the Baseline Visit.

    Type de données

    boolean

    Alias
    UMLS CUI [1]
    C2348568
    15. Subjects who, in the opinion of the investigator, would be non-compliant with the visit schedule or other study procedures.
    Description

    15. Subjects non-compliant with the visit schedule or other study procedures.

    Type de données

    boolean

    Alias
    UMLS CUI [1,1]
    C1321605
    UMLS CUI [1,2]
    C2348563
    17. Women who have a positive pregnancy test or who are lactating.
    Description

    17. Women who have a positive pregnancy test or who are lactating.

    Type de données

    boolean

    Alias
    UMLS CUI [1]
    C0032961
    UMLS CUI [2]
    C2828358
    18. Women of child-bearing potential who are not practicing a clinically accepted method of contraception such as oral contraception, surgical sterilization, IUD, diaphragm in conjunction with spermicidal foam and condom on the male partner, or systemic contraception (e.g. Norplant).
    Description

    18. Women of child-bearing potential who are not practicing a clinically accepted method of contraception.

    Type de données

    boolean

    Alias
    UMLS CUI [1]
    C1960468
    UMLS CUI [2,1]
    C0700589
    UMLS CUI [2,2]
    C3176353
    UMLS CUI [3]
    C0029151
    UMLS CUI [4]
    C0015787
    UMLS CUI [5]
    C0021900
    UMLS CUI [6,1]
    C0042241
    UMLS CUI [6,2]
    C3843423
    UMLS CUI [6,3]
    C0009653
    UMLS CUI [7,1]
    C0700589
    UMLS CUI [7,2]
    C1515119
    Retour au début de la page

    Similar models

    Baseline - Eligibility Question

    1 Formulaires
    Name
    Type
    Description | Question | Decode (Coded Value)
    Type de données
    Alias
    Item Group
    Eligibility Question
    C1516637 (UMLS CUI-1)
    Did the subject meet all the entry criteria?
    Item
    Did the subject meet all the entry criteria?
    boolean
    C1516637 (UMLS CUI [1])
    Item Group
    Inclusion Criteria
    C1512693 (UMLS CUI-1)
    1. Subjects diagnosed with RLS using the RLS Diagnostic Clinical Interview and the International RLS Study Group (IRLSSG) Diagnostic Criteria at the Screening Visit.
    Item
    1. Subjects diagnosed with RLS using the RLS Diagnostic Clinical Interview and the International RLS Study Group (IRLSSG) Diagnostic Criteria at the Screening Visit.
    boolean
    C0035258 (UMLS CUI [1])
    C1537061 (UMLS CUI [2,1])
    C0035258 (UMLS CUI [2,2])
    2. Subjects > 18 years and < 80 years of age
    Item
    2. Subjects > 18 years and < 80 years of age.
    boolean
    C0001779 (UMLS CUI [1])
    3. Restless Legs Syndrome; Frequencies (time pattern) | Restless Legs Syndrome; Pharmaceutical Preparations; Washout Period
    Item
    3. Subjects have had RLS symptoms with a history of a minimum of 20 evening and nights of RLS episodes during the month prior to the Screening Visit (e.g., any combination of evenings and/or nights for >20 days). In the case of a subject currently receiving medication for the treatment of RLS at the Screening Visit, this inclusion criterion can be waived. However, the subject must discontinue and washout any previous medication for the treatment of RLS or sleep prior to the Baseline Visit (Day 0). The minimum discontinuation period for washout is generally 5 half-lives of the medication or 7 consecutive nights medication-free prior to baseline, whichever is the longer period.
    boolean
    C0035258 (UMLS CUI [1,1])
    C0439603 (UMLS CUI [1,2])
    C0035258 (UMLS CUI [2,1])
    C0013227 (UMLS CUI [2,2])
    C1710661 (UMLS CUI [2,3])
    4.During the Washout and Screening Phase, RLS symptoms must be present for at least 4 of the last 7 evening and nights immediately prior to the Baseline Visit (e.g., any combination of evenings and/or nights for >4 days).
    Item
    4.During the Washout and Screening Phase, RLS symptoms must be present for at least 4 of the last 7 evening and nights immediately prior to the Baseline Visit (e.g., any combination of evenings and/or nights for >4 days).
    boolean
    C1710661 (UMLS CUI [1,1])
    C0035258 (UMLS CUI [1,2])
    C0439603 (UMLS CUI [1,3])
    C0220908 (UMLS CUI [2,1])
    C0035258 (UMLS CUI [2,2])
    C0439603 (UMLS CUI [2,3])
    5.Subjects with a total score > 15 on the IRLS Rating Scale at baseline.
    Item
    5.Subjects with a total score > 15 on the IRLS Rating Scale at baseline.
    boolean
    C0449820 (UMLS CUI [1,1])
    C0681889 (UMLS CUI [1,2])
    C0035258 (UMLS CUI [1,3])
    6.Subjects with RLS symptoms that cause significant sleep impairment based on clinical judgment and guided by subject response to question 4 of the IRLS Rating Scale (e.g., Ordinarily this will include a response of (3) severe or (4) very severe sleep disturbance) at the Baseline Visit.
    Item
    6.Subjects with RLS symptoms that cause significant sleep impairment based on clinical judgment and guided by subject response to question 4 of the IRLS Rating Scale (e.g., Ordinarily this will include a response of (3) severe or (4) very severe sleep disturbance) at the Baseline Visit.
    boolean
    C0035258 (UMLS CUI [1,1])
    C0851578 (UMLS CUI [1,2])
    7.Subjects must be experiencing RLS symptoms requiring treatment prior to bedtime, but no earlier than 5:00 PM.
    Item
    7.Subjects must be experiencing RLS symptoms requiring treatment prior to bedtime, but no earlier than 5:00 PM.
    boolean
    C0035258 (UMLS CUI [1,1])
    C1457887 (UMLS CUI [1,2])
    C0332121 (UMLS CUI [1,3])
    C0521112 (UMLS CUI [1,4])
    8. Subjects must have given written informed consent prior to any specific study procedures.
    Item
    8. Subjects must have given written informed consent prior to any specific study procedures.
    boolean
    C0021430 (UMLS CUI [1])
    Item Group
    Exclusion criteria
    C0680251 (UMLS CUI-1)
    1. Subjects requiring treatment of daytime RLS symptoms (daytime defined as 7:00 AM until 5:00 PM).
    Item
    1. Subjects requiring treatment of daytime RLS symptoms (daytime defined as 7:00 AM until 5:00 PM).
    boolean
    C0035258 (UMLS CUI [1,1])
    C0087111 (UMLS CUI [1,2])
    C1457887 (UMLS CUI [1,3])
    C0332169 (UMLS CUI [1,4])
    2. Signs of secondary RLS (e.g. end stage renal disease, iron deficient anemia or pregnancy at Baseline Visit).
    Item
    2. Signs of secondary RLS (e.g. end stage renal disease, iron deficient anemia or pregnancy at Baseline Visit).
    boolean
    C1261469 (UMLS CUI [1])
    C0022661 (UMLS CUI [2])
    C0162316 (UMLS CUI [3])
    C0032961 (UMLS CUI [4])
    3. Subjects with a serum ferritin level of < 10 mcg/L (ng/mL) that has not resolved by the time of the Baseline Visit.
    Item
    3. Subjects with a serum ferritin level of < 10 mcg/L (ng/mL) that has not resolved by the time of the Baseline Visit.
    boolean
    C0696113 (UMLS CUI [1])
    Laboratory test result abnormal; Clinical Significance | Electrocardiogram abnormal; Clinical Significance | Physical Examination; Abnormal; Clinical Significance | Myocardial Ischemia | Abnormal cardiac conduction; Clinical Significance | Cardiac Arrhythmia; Clinical Significance
    Item
    4. Subjects having a clinically significant abnormal lab, ECG, or physical exam findings not resolved by time of baseline examinations. Abnormal 12-lead ECG findings include, but are not limited to the following: myocardial ischemia, clinically significant conduction abnormalities, or clinically significant arrhythmias
    boolean
    C0438215 (UMLS CUI [1,1])
    C2826293 (UMLS CUI [1,2])
    C0522055 (UMLS CUI [2,1])
    C2826293 (UMLS CUI [2,2])
    C0031809 (UMLS CUI [3,1])
    C0205161 (UMLS CUI [3,2])
    C2826293 (UMLS CUI [3,3])
    C0151744 (UMLS CUI [4])
    C0232219 (UMLS CUI [5,1])
    C2826293 (UMLS CUI [5,2])
    C0003811 (UMLS CUI [6,1])
    C2826293 (UMLS CUI [6,2])
    5. Subjects who suffer from a primary sleep disorder other than RLS that may significantly affect the symptoms of RLS (e.g. narcolepsy, sleep terror disorder, sleepwalking disorder, breathing related sleep disorder).
    Item
    5. Subjects who suffer from a primary sleep disorder other than RLS that may significantly affect the symptoms of RLS (e.g. narcolepsy, sleep terror disorder, sleepwalking disorder, breathing related sleep disorder).
    boolean
    C0236991 (UMLS CUI [1,1])
    C0035258 (UMLS CUI [1,2])
    C0205394 (UMLS CUI [1,3])
    C0035258 (UMLS CUI [2,1])
    C1457887 (UMLS CUI [2,2])
    C0027404 (UMLS CUI [3])
    C0851578 (UMLS CUI [4,1])
    C0037320 (UMLS CUI [4,2])
    C0037672 (UMLS CUI [5])
    C0236845 (UMLS CUI [6])
    6. Subjects diagnosed with movement disorders (e.g. Parkinson’s Disease, dyskinesias, and dystonias).
    Item
    6. Subjects diagnosed with movement disorders (e.g. Parkinson’s Disease, dyskinesias, and dystonias).
    boolean
    C0026650 (UMLS CUI [1])
    C0030567 (UMLS CUI [2])
    C0013384 (UMLS CUI [3])
    C0013421 (UMLS CUI [4])
    7. Subjects who have medical conditions which, in the opinion of the investigator, could affect efficacy assessments or clinically significant or unstable medical conditions that present a safety concern.
    Item
    7. Subjects who have medical conditions which, in the opinion of the investigator, could affect efficacy assessments or clinically significant or unstable medical conditions that present a safety concern. These may include, but are not limited to the following disorders: diabetes, peripheral neuropathy, rheumatoid arthritis, fibromyalgia syndrome, symptomatic orthostatic hypotension, severe cardiovascular disease, hepatic or renal failure, pleuro-pulmonary fibrosis).
    boolean
    C0012634 (UMLS CUI [1,1])
    C1280519 (UMLS CUI [1,2])
    C0220825 (UMLS CUI [1,3])
    C0012634 (UMLS CUI [2,1])
    C0443343 (UMLS CUI [2,2])
    C0036043 (UMLS CUI [2,3])
    C2699424 (UMLS CUI [2,4])
    C0011849 (UMLS CUI [3])
    C0031117 (UMLS CUI [4])
    C0003873 (UMLS CUI [5])
    C0016053 (UMLS CUI [6])
    C0740482 (UMLS CUI [7])
    C0007222 (UMLS CUI [8,1])
    C0205082 (UMLS CUI [8,2])
    C0035078 (UMLS CUI [9])
    C0085605 (UMLS CUI [10])
    C0034069 (UMLS CUI [11])
    8.Subjects with augmentation and/or end-of-dose rebound symptoms at baseline.
    Item
    8.Subjects with augmentation and/or end-of-dose rebound symptoms at baseline. Augmentation is defined as RLS symptoms that occurred while on treatment and occur >2 hours earlier than they did before, symptoms which are more severe than when not treated, symptoms which start after less time at rest than they did before treatment, or symptoms which involve other parts of the body, such as the arms or trunk.
    boolean
    C1293122 (UMLS CUI [1])
    C0549262 (UMLS CUI [2])
    C0035258 (UMLS CUI [3,1])
    C1457887 (UMLS CUI [3,2])
    C2745955 (UMLS CUI [3,3])
    C0035258 (UMLS CUI [4,1])
    C1457887 (UMLS CUI [4,2])
    C0205082 (UMLS CUI [4,3])
    C0035258 (UMLS CUI [5,1])
    C1457887 (UMLS CUI [5,2])
    C0229962 (UMLS CUI [5,3])
    9. Subjects with a history of alcohol or substance abuse within the past year.
    Item
    9. Subjects with a history of alcohol or substance abuse within the past year.
    boolean
    C0085762 (UMLS CUI [1,1])
    C1299544 (UMLS CUI [1,2])
    10. Subjects with a diastolic blood pressure >110mmHg or <50mmHg or systolic blood pressure > 180mmHg or <90mmHg at the Screening or Baseline Visit.
    Item
    10. Subjects with a diastolic blood pressure >110mmHg or <50mmHg or systolic blood pressure > 180mmHg or <90mmHg at the Screening or Baseline Visit.
    boolean
    C0428883 (UMLS CUI [1])
    C0871470 (UMLS CUI [2])
    11. Subjects taking any medication known to induce drowsiness, affect RLS or sleep and that have not been discontinued prior to the Baseline Visit.
    Item
    11. Subjects taking any medication known to induce drowsiness, affect RLS or sleep and that have not been discontinued prior to the Baseline Visit. These medications include the following: - antidepressants (tricyclic antidepressants, noradrenaline [norepinephrine]/ serotonin re-uptake inhibitors, selective serotonin re-uptake inhibitors, bupropion), anticonvulsants, opioids (including propoxyphene and oxycodone), anxiolytics, all sedatives/hypnotics (including benzodiazepines), lithium, oral neuroleptics, stimulants (including methylphenidate), antipsychotics, dopamine agonists, dopamine antagonists, clonidine, and sedating antihistamines (e.g. chlorpheniramine, diphenhydramine, hydroxyzine) or any preparations containing these antihistamines - The minimum discontinuation period is generally 5 half lives or 7 consecutive evening/nights medication free, prior to baseline, whichever is the longer period. Exceptions to this general rule are as follows: fluoxetine, monoamine oxidase inhibitors: 4 weeks; depot neuroleptics: 12 weeks. - Exceptions may be made in the case of subjects who have been taking stable doses of one of the excluded medications for at least 3 months prior to study start and it can be confirmed that the medication is not affecting the subject’s symptoms of RLS or sleep. These exceptions will be made on a case by case basis after consultation with the sponsor. For these exceptions, the dose of the excluded medication must remain stable throughout the duration of the study.
    boolean
    C0013227 (UMLS CUI [1,1])
    C0013144 (UMLS CUI [1,2])
    C0035258 (UMLS CUI [1,3])
    C0392760 (UMLS CUI [1,4])
    C0013227 (UMLS CUI [1,5])
    C0013144 (UMLS CUI [1,6])
    C0035258 (UMLS CUI [1,7])
    C0037313 (UMLS CUI [1,8])
    C0457454 (UMLS CUI [1,9])
    C0003290 (UMLS CUI [2])
    C0162758 (UMLS CUI [3])
    C0003286 (UMLS CUI [4])
    C0242402 (UMLS CUI [5,1])
    C0033493 (UMLS CUI [5,2])
    C0030049 (UMLS CUI [5,3])
    C0040616 (UMLS CUI [6])
    C0020592 (UMLS CUI [7,1])
    C0005064 (UMLS CUI [7,2])
    C0023870 (UMLS CUI [8])
    C0040615 (UMLS CUI [9,1])
    C0442027 (UMLS CUI [9,2])
    C0304402 (UMLS CUI [10,1])
    C0025810 (UMLS CUI [10,2])
    C0040615 (UMLS CUI [11])
    C0178601 (UMLS CUI [12])
    C0242702 (UMLS CUI [13])
    C0009014 (UMLS CUI [14])
    C1955826 (UMLS CUI [15,1])
    C0008281 (UMLS CUI [15,2])
    C0012522 (UMLS CUI [15,3])
    C0020404 (UMLS CUI [15,4])
    C0457454 (UMLS CUI [16,1])
    C1524031 (UMLS CUI [16,2])
    C0016365 (UMLS CUI [17])
    C0026457 (UMLS CUI [18])
    C0040615 (UMLS CUI [19,1])
    C0086129 (UMLS CUI [19,2])
    12. Withdrawal, introduction, or change in dose of hormone replacement therapy (HRT) and/or any drug known to substantially inhibit CYP1A2 (e.g. ciprofloxacin, cimetidine, fluvoxamine, HRT) or induce CYP1A2 (e.g. tobacco, omeprazole) within 7 days prior to Baseline Visit.
    Item
    12. Withdrawal, introduction, or change in dose of hormone replacement therapy (HRT) and/or any drug known to substantially inhibit CYP1A2 (e.g. ciprofloxacin, cimetidine, fluvoxamine, HRT) or induce CYP1A2 (e.g. tobacco, omeprazole) within 7 days prior to Baseline Visit. Subjects already on these agents may be enrolled, but must remain on stable doses of the agents from 7 days prior to Baseline Visit through to the follow-up visit at end of study.
    boolean
    C0282402 (UMLS CUI [1,1])
    C2349954 (UMLS CUI [1,2])
    C0282402 (UMLS CUI [2,1])
    C0579004 (UMLS CUI [2,2])
    C0282402 (UMLS CUI [3,1])
    C1707811 (UMLS CUI [3,2])
    C1827504 (UMLS CUI [4,1])
    C0008809 (UMLS CUI [4,2])
    C0008783 (UMLS CUI [4,3])
    C0085228 (UMLS CUI [4,4])
    C0282402 (UMLS CUI [4,5])
    C1827490 (UMLS CUI [5,1])
    C0543414 (UMLS CUI [5,2])
    C0028978 (UMLS CUI [5,3])
    13. Subjects who have exhibited intolerance to ropinirole or any other dopamine agonist.
    Item
    13. Subjects who have exhibited intolerance to ropinirole or any other dopamine agonist.
    boolean
    C1744706 (UMLS CUI [1,1])
    C0244821 (UMLS CUI [1,2])
    C1744706 (UMLS CUI [2,1])
    C0178601 (UMLS CUI [2,2])
    14. Night workers or any others whose sleeping habits are incompatible with the study design, or who would be required to make significant changes to their bedtime during the course of the study.
    Item
    14. Night workers or any others whose sleeping habits are incompatible with the study design, or who would be required to make significant changes to their bedtime during the course of the study.
    boolean
    C0555008 (UMLS CUI [1])
    C0547101 (UMLS CUI [2,1])
    C4698019 (UMLS CUI [2,2])
    C0035171 (UMLS CUI [2,3])
    C0547101 (UMLS CUI [3,1])
    C4698019 (UMLS CUI [3,2])
    C0680104 (UMLS CUI [3,3])
    15. Participation in any clinical drug or device trial in the one month prior to the Baseline Visit.
    Item
    15. Participation in any clinical drug or device trial in the one month prior to the Baseline Visit.
    boolean
    C2348568 (UMLS CUI [1])
    15. Subjects non-compliant with the visit schedule or other study procedures.
    Item
    15. Subjects who, in the opinion of the investigator, would be non-compliant with the visit schedule or other study procedures.
    boolean
    C1321605 (UMLS CUI [1,1])
    C2348563 (UMLS CUI [1,2])
    17. Women who have a positive pregnancy test or who are lactating.
    Item
    17. Women who have a positive pregnancy test or who are lactating.
    boolean
    C0032961 (UMLS CUI [1])
    C2828358 (UMLS CUI [2])
    18. Women of child-bearing potential who are not practicing a clinically accepted method of contraception.
    Item
    18. Women of child-bearing potential who are not practicing a clinically accepted method of contraception such as oral contraception, surgical sterilization, IUD, diaphragm in conjunction with spermicidal foam and condom on the male partner, or systemic contraception (e.g. Norplant).
    boolean
    C1960468 (UMLS CUI [1])
    C0700589 (UMLS CUI [2,1])
    C3176353 (UMLS CUI [2,2])
    C0029151 (UMLS CUI [3])
    C0015787 (UMLS CUI [4])
    C0021900 (UMLS CUI [5])
    C0042241 (UMLS CUI [6,1])
    C3843423 (UMLS CUI [6,2])
    C0009653 (UMLS CUI [6,3])
    C0700589 (UMLS CUI [7,1])
    C1515119 (UMLS CUI [7,2])
    Retour au début de la page 

    Aide

    Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

    Watch Tutorial